Mannkind UBS Global Biopharma Conference 2026
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Always great. Great. Good day, everybody.
Welcome back to UBS Biopharma Conference in London, and really excited to have MannKind here. My name is Ash Verma, and with me I have Michael Castagna, who is the CEO of the company. Thanks, Mike, for joining us.
Thank you for having us.
Appreciate it. Great. A lot of people are kind of familiar with your story as well, but just maybe if you can give, hit a couple of key highlights of some of the recent updates coming out of third quarter earnings, and then we can take it from there.
Sure. For those who do not know the company, it is originally based on a DPI platform of inhalation technologies. We have evolved with purchasing an injectable product called FUROSCIX, and that has been a big highlight here for Q3. The company is really broken down into three different businesses as you think about it. We have a royalty manufacturing stream with a partnership with United. We have a diabetes franchise with the history of AFREZZA, and then we got the FUROSCIX in the commercial side, and then you got the third arm is the pipeline, which is around the inhaled nintedanib, so that is exciting.
Great. Awesome. Maybe just if I talk about the FUROSCIX. What made this brand as a strategic fit for you, and some of the early launch metrics that you are looking at, what drives your conviction that there is more long-term growth opportunity here?
Yeah. I think when you look, MannKind has been looking like we have this wonderful royalty coming in. How do we best deploy that capital to grow the company even faster? That has been one of our conscious efforts is looking for ways to diversify our revenue stream, number 1. But number 2, where can we add value? Where can we do something different than what was being done? That is where scPharmaceuticals came in. We were able to purchase that at a decent price last year, bring that in, and the big upside here was ReadyFlow, and we just got that approved here in Q3. So I think you can see MannKind focus on launching new products. We just launched pediatrics AFREZZA in really Q3, and then you got FUROSCIX here in Q3. That was a really exciting time.
So the really focus there was how quickly could you convert the patients and how much upside can we deliver from where we are. I think you can see in the first really six weeks after launch, we drove almost 75%-80% conversion to ReadyFlow from the on-body infusor, which is amazing. That came in a couple quarters ahead of our expectations, which is great to see that execution there. Then you got Q4, which should be our best quarter ever in terms of ReadyFlow plus the company.
Great. That is great. Is that part of the broader strategy for the platform that you want to bring in more products? I mean, you have DPI, which is like a pretty amazing source of several revenue opportunities, but in terms of additional BD, could you see yourself doing more of these type of things?
Yeah. Things have come up a little bit in price the past year, so I think as we see things moderate a little bit, there will be opportunities there. We are not in a rush to buy anything, but we have been very patient. We looked for a couple years before we bought scPharmaceuticals. I think we have enough on our plate that we can execute really well right now for the next 12 to 18 months with everything we are doing for MNKD-201 launch and getting prepared for the trial, plus the FUROSCIX, plus AFREZZA. If we see stuff we can bolt onto those businesses, I think that will be the main focus here. But just executing the launches in front of us will be the core focus that we got to deliver on.
Got it. Okay. Can you elaborate on the FUROSCIX, the new format that you launched with this autoinjector, right? How does that actually benefit compared to the on-body format that you had before?
Yeah. I think being able to innovate something that has been around. The Lasix molecule has been around for 60 years, right? When you look and say, "What is the unmet need you are solving?" The on-body infusor was the first time in 60 years where we can get people out of the hospital. When you are sitting in the hospital, you are at risk for infections, you are at risk for drug interactions, you are at risk for a lot of things. So, that is the goal for ultimately the products that were created. So on-body infusor was the very first time we could potentially stop people from going into the hospital, and that is where 90% of the sales were on that product. About 10% were in the, I will say, hospital setting. With ReadyFlow, we think we really open up that hospital segment.
When you look at the big opportunity in front of us, it is the million hospitalizations a year, and it is the re-hospitalizations. That is where the biggest pain points are in health systems. When you think about 800,000 hospitalizations growing every year, these people get really sick. Unfortunately, about 5%-10% die. If we can get them out of the hospital, we are saving lives, we are reducing complications, we are helping the entire system. If you look, there is just not a lot of beds. The ERs are backed up. This really helps bring efficiencies into a health system. I think that is when you start looking and saying, "How many hospitalizations are because of heart failure or fluid overload?" I think it is like 40%-50%. It is just a big number.
If we can start to make impact there, we really free up a lot of capacity in health systems. That is why it is such a big opportunity as we look at that next segment of growth. ReadyFlow really opens up that opportunity more so than ever.
Great. ReadyFlow has been great. Then you have a 40 mg presentation that you are also looking at. Just how would that change the value proposition?
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
2 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
